CIK 0001885522
- Non-accelerated filer
- Smaller reporting company
Neumora Therapeutics, Inc.
Sign in to watch- Ticker
- NMRA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 844367680
- Phone
- +1 857-760-0900
- Business address
- 260 ARSENAL PLACE, SUITE 1, WATERTOWN, MA, 02472
- 4 Open-market buy Director bought 140,605 shares at an average $10.98 ($1,543,563)
- 4 Open-market buy 10% owner bought 140,605 shares at an average $10.98 ($1,543,563)
- 4 Open-market buy Director bought 95,694 shares at an average $11.49 ($1,099,945)
- 4 Open-market buy 10% owner bought 95,694 shares at an average $11.49 ($1,099,945)
- 4 Open-market buy Director bought 76,511 shares at an average $13.68 ($1,046,848)
- 4 Open-market buy 10% owner bought 76,511 shares at an average $13.68 ($1,046,848)
- 4 Open-market buy Director bought 58,504 shares at an average $11.97 ($700,464)
- 4 Open-market buy 10% owner bought 58,504 shares at an average $11.97 ($700,464)
- 4 Open-market buy 10% owner bought 100,740 shares at an average $11.19 ($1,127,064)
- 4 Open-market buy Director bought 100,740 shares at an average $11.19 ($1,127,064)
- 4 Conversion FMR LLC acquired 3,712,624 shares (conversion)
- 4 Open-market buy Director bought 1,500,000 shares at $17.00 ($25,500,000)
- 4 Open-market buy 10% owner bought 1,500,000 shares at $17.00 ($25,500,000)
- 4 Open-market buy 10% owner bought 1,500,000 shares at $17.00 ($25,500,000)
- 4 Open-market buy President & CEO bought 15,000 shares at $12.62 ($189,371)
- 4 Open-market buy 10% owner bought 1,764,705 shares at $17.00 ($29,999,985)
- 4 Grant or award Head of R&D acquired 352,941 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 5 of 6 · 118 filings